Compare Moderna, Inc. (MRNA) vs Orion Office REIT Inc (ONL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Orion Office REIT Inc — how do they compare? Moderna, Inc. trades at $135.89 (market cap $56.02B), while Orion Office REIT Inc trades at $2.55 (market cap $151.74M). The key difference: Moderna, Inc. is far larger — about 369.2× Orion Office REIT Inc's market cap, and Orion Office REIT Inc pays a 3.01% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | ONL | |
|---|---|---|
Market Cap | $56.02B | $151.74M |
Sector | Health | Real Estate |
52-Week High | $174.38 | $3.00 |
52-Week Low | $22.36 | $1.93 |
Enterprise Value | $52.17B | $568.67M |
Dividend Yield | — | 3.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $140.33, down 3.59% on the day, but maintains a bullish technical signal with support at $138 and resistance at $145. Recent positive phase 3 cancer vaccine trial results have driven significant stock appreciation, though financials show declining revenue and negative net income margins. The company has beaten EPS estimates for the last three quarters, with Q3 2026 results pending.
The outlook is mixed; promising clinical developments in oncology offer long-term growth potential, but high valuation multiples and persistent losses pose risks. Analyst consensus is cautious with a $90.08 price target below the current price, reflecting concerns over profitability and competitive pressures in the mRNA therapeutics space.
Orion Office REIT (ONL) trades at $2.66, down 1.85% on the day, with a bearish technical outlook and mixed fundamentals. The company reported a Q2 2026 earnings beat but continues to post significant net losses, with a negative net income margin of -65.66% in 2025. Despite a low price-to-book ratio of 0.24, indicating potential undervaluation, declining revenues and negative profitability metrics highlight ongoing challenges in its office property portfolio.
The outlook remains cautious due to persistent operational losses and high debt levels, though analyst sentiment is split evenly between Buy and Hold. Key risks include further revenue erosion and interest expense pressures, while potential catalysts hinge on successful portfolio repositioning and stabilized office demand as highlighted in recent earnings calls.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Orion Office REIT Inc
Orion Office REIT Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased primarily on a single-tenant net lease basis to creditworthy clients.
Read more on ONL →
